Cover Image


Veranova, L.P. Applies to Manufacture Controlled Substances in Bulk

Estimated reading time: 2–3 minutes

Veranova, L.P. has sent an application to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of several controlled substances. The request was made on April 17, 2025.

The proposed location for manufacturing is 25 Patton Road, Pharmaceutical Service, Devens, Massachusetts 01434-3803. The company seeks to produce the following basic classes of controlled substances:

  • Lysergic Acid Diethylamide (LSD) (Drug Code 7315), Schedule I
  • 3,4-Methylenedioxymethamphetamine (MDMA) (Drug Code 7405), Schedule I
  • Dimethyltryptamine (Drug Code 7435), Schedule I
  • Amphetamine (Drug Code 1100), Schedule II
  • Methylphenidate (Drug Code 1724), Schedule II
  • Nabilone (Drug Code 7379), Schedule II
  • Hydrocodone (Drug Code 9193), Schedule II
  • Levorphanol (Drug Code 9220), Schedule II
  • Thebaine (Drug Code 9333), Schedule II
  • Alfentanil (Drug Code 9737), Schedule II
  • Remifentanil (Drug Code 9739), Schedule II
  • Sufentanil (Drug Code 9740), Schedule II

The DEA states that Veranova plans to use the substances to support manufacturing and analytical testing at its other DEA-registered manufacturing facility. No other activities for these drug codes are authorized under this registration.

Anyone who is a registered bulk manufacturer of these drugs, or is applying to become one, can submit comments or object to the proposed registration. Comments and objections must be sent electronically by August 1, 2025.

To submit a comment, visit https://www.regulations.gov and follow the instructions. Once a comment is submitted, you will get a Comment Tracking Number as proof. Comments may not appear immediately online.

A written request for a hearing about this application must also be filed by the deadline.

This notice was signed by Matthew Strait, Deputy Assistant Administrator at the DEA. The official notice is document number 2025-09929 and was published in the Federal Register Volume 90, Number 104, on June 2, 2025.


Legal Disclaimer

This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.